We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

3 28 13

The last few weeks have started the same, and that’s with a list of penny stocks with potential catalysts. One of the exciting things about specific industries like biotech is that companies tend to pre-announce a date that news will come out in the future. Whether it’s something like a Prescription Drug User Fee Act (PDUFA) date with the FDA or new data readouts, there are many things to monitor. In most cases, biotech companies will give the public the timing of things like these.

The important part is deciding if upcoming events are potential bullish or bearish catalysts. As I’m sure many of you already know, biotech is a fickle area of the market. Companies can come out with positive data, but if one thing’s missed or came up short of expectations, a would-be optimistic report can become the reason penny stocks sell off. Last week we discussed 10 Top Penny Stocks To Watch With Potential Biotech Catalysts. Of those stocks discussed, some climbed to new September highs while others fell short. But the more you know, the better prepared you’ll be for what could be in store.

Read more: Top Penny Stocks To Watch Under $1 In October 2021

In this article, we’ll look at 5 penny stocks to watch this week with potential catalysts. Some have given specific dates, while others have shown a timeframe. After you get the lay of the land, then you can decide for yourself if they’re the best penny stocks to buy this week or if you should avoid them entirely.

The first name on this list of penny stocks to watch this week is Arbutus. We’ve discussed the company plenty of times. If you’re not familiar, however, let’s get you up to speed. Arbutus focuses on treatments for chronic infections, including hepatitis B, and new therapies for treating coronaviruses. A fair amount of attention has been on Arbutus versus Moderna, believe it or not. The two conflicted over Arbutus’s lipid formulations for nucleic acid delivery.

Last month, the European Patent Office said that its 069 patent related to lipid formulations was........

© Entrepreneur

Get it on Google Play